A PHASE 1/2 STUDY OF MT‐3724 TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF MT‐3724 FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019)